Anavex Life Sciences Corp (AVXL)

[falconer66a]

The lack of evidence of unsafety or inefficacy.

..."are there any credible contradictions out in the scientific community to any AVXL claims?"

This, exactly, is what I spent many hours looking for, when I first heard of Anavex and Anavex 2-73. Too good to be true. There had to be unrevealed or poorly-described negative factors with the drug. Yes, it works in nerves and the CNS, so there almost surely must be side effects and/or efficacy complications—the case with virtually all CNS drugs (even aspirin).

So, I searched PubMed and all the other academic info sources to learn everything I could about the drug. There were lots of papers and data. But missing in every single one of them was any discovery or mention of complicating side effects. The drug didn’t (and doesn’t) have any. For a powerful CNS drug, “too good to be true.”

But in all of the papers were the opposite: presentation of data showing degrees of efficacy. The drug works therapeutically.

But, please note. It would be one thing for a proponent of Anavex (myself) to proclaim both safety and efficacy; but quite another for an Anavex naysayer to lay out the drug’s safety and efficacy problems. Seen any of those recently? Of course not. They don’t exist.

Dare I say, there is now universal agreement on blarcamesine’s safety. No one, proponent or basher, has posted any side effects problems with the drug for some time. None can be found, by anyone, pro or con. Then, when the Rett study data are released, no one will be able to claim that blarcamesine can’t fix things in diseased nerves.

My proclamations of blarcamesine safety and efficacy are valid. But the even greater matter is the inability of Anavex opponents to lay out and describe information that negates those contentions. If there were any safety problems, we’d have heard about them. The silence on that matter is definitive, altogether. Next, and finally, will be the Rett study data, conclusively and universally proving therapeutic efficacy.

For traditional CNS drug therapies, game over.